Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —

—The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies  —